AgeX Therapeutics Company

AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.
Technology: Geroscience
Industry: Stem cell therapies
Headquarters: United States
Founded Date: 2017-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 7
Total Funding: $63.8M
Estimated Revenue: Less than $1M
Last Funding Type: Private Equity

Visit Website
INFO@AGEXINC.COM
https://twitter.com/agexthera
Register and Claim Ownership